King Altace Label Highlights Data Supporting Efficacy In Diabetic Patients
Executive Summary
Labeling for King Pharmaceutical's ACE inhibitor Altace has been updated to highlight substudy data supporting efficacy in diabetic patients, following FDA approval Oct. 5 for reduction in risk of myocardial infarction, stroke and death from cardiovascular causes.
You may also be interested in...
Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT
FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies
Antihypertensive Outcomes Labeling Emphasized By FDA After ALLHAT
FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies
King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth
Prescriptions for King's ACE inhibitor Altace (ramipril) are shifting to the 10 mg strength, the same dose used in the Heart Outcomes Prevention Evaluation study, CEO Jefferson Gregory said